FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311658429> ?p ?o ?g. }

• W4311658429 endingPage "1746" @default.
• W4311658429 startingPage "1735" @default.
• W4311658429 abstract "PURPOSE Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)–expressing esophageal squamous cell carcinoma (ESCC) by the European Medicines Agency, whereas the US Food and Drug Administration approved this regimen regardless of PD-L1 expression. The superiority of programmed death-1 (PD-1) antibody plus chemotherapy over chemotherapy alone in patients with low PD-L1–expressing ESCC remains debatable. METHODS Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to identify eligible randomized controlled trials for meta-analysis. Study-level pooled analyses of hazard ratios (HRs) for overall survival and progression-free survival and odds ratios for objective response rate according to PD-L1 expression were performed. RESULTS The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1–expressing subgroups. Five randomized controlled trials were included in the meta-analysis, and two PD-L1 expression scoring criteria, TPS (≥ 1%/< 1%) and combined positive score (CPS, ≥ 10/< 10), were analyzed. Significant overall survival benefit by adding PD-1 antibody to chemotherapy was observed in both the TPS < 1% (HR, 0.74; 95% CI, 0.56 to 0.97) and CPS < 10 (HR, 0.77; 95% CI, 0.66 to 0.89) subgroups. Similarly, significantly prolonged progression-free survival was observed in both the TPS < 1% (HR, 0.66; 95% CI, 0.50 to 0.86) and CPS < 10 (HR, 0.63; 95% CI, 0.47 to 0.84) subgroups. In addition, the objective response rate of the TPS < 1% subgroup was significantly improved (odds ratio, 1.71; 95% CI, 1.27 to 2.29). In all high PD-L1–expressing subgroups, the pooled benefit of PD-1 antibody plus chemotherapy was significantly better than that of chemotherapy. CONCLUSION This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of predictive biomarkers are warranted." @default.
• W4311658429 created "2022-12-27" @default.
• W4311658429 creator A5007037906 @default.
• W4311658429 creator A5014846775 @default.
• W4311658429 creator A5028365943 @default.
• W4311658429 creator A5031097466 @default.
• W4311658429 creator A5033004974 @default.
• W4311658429 creator A5054280511 @default.
• W4311658429 creator A5067433800 @default.
• W4311658429 creator A5072459089 @default.
• W4311658429 creator A5084421656 @default.
• W4311658429 creator A5085802645 @default.
• W4311658429 date "2023-03-20" @default.
• W4311658429 modified "2023-10-17" @default.
• W4311658429 title "Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis" @default.
• W4311658429 cites W1982488143 @default.
• W4311658429 cites W2557730509 @default.
• W4311658429 cites W2560367415 @default.
• W4311658429 cites W2572174216 @default.
• W4311658429 cites W2635951006 @default.
• W4311658429 cites W2767298971 @default.
• W4311658429 cites W2789258259 @default.
• W4311658429 cites W2796582438 @default.
• W4311658429 cites W2804957255 @default.
• W4311658429 cites W2892640821 @default.
• W4311658429 cites W2906166963 @default.
• W4311658429 cites W2954094199 @default.
• W4311658429 cites W2957409472 @default.
• W4311658429 cites W2976652879 @default.
• W4311658429 cites W2978609674 @default.
• W4311658429 cites W3025003676 @default.
• W4311658429 cites W3089892480 @default.
• W4311658429 cites W3092384992 @default.
• W4311658429 cites W3109638148 @default.
• W4311658429 cites W3128131226 @default.
• W4311658429 cites W3128646645 @default.
• W4311658429 cites W3195935456 @default.
• W4311658429 cites W3200109370 @default.
• W4311658429 cites W3208828613 @default.
• W4311658429 cites W4211048478 @default.
• W4311658429 cites W4211125721 @default.
• W4311658429 cites W4213300728 @default.
• W4311658429 cites W4214915284 @default.
• W4311658429 cites W4224213460 @default.
• W4311658429 cites W4224260137 @default.
• W4311658429 cites W4226136872 @default.
• W4311658429 cites W4249441028 @default.
• W4311658429 cites W4283771980 @default.
• W4311658429 doi "https://doi.org/10.1200/jco.22.01490" @default.
• W4311658429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36473145" @default.
• W4311658429 hasPublicationYear "2023" @default.
• W4311658429 type Work @default.
• W4311658429 citedByCount "10" @default.
• W4311658429 countsByYear W43116584292023 @default.
• W4311658429 crossrefType "journal-article" @default.
• W4311658429 hasAuthorship W4311658429A5007037906 @default.
• W4311658429 hasAuthorship W4311658429A5014846775 @default.
• W4311658429 hasAuthorship W4311658429A5028365943 @default.
• W4311658429 hasAuthorship W4311658429A5031097466 @default.
• W4311658429 hasAuthorship W4311658429A5033004974 @default.
• W4311658429 hasAuthorship W4311658429A5054280511 @default.
• W4311658429 hasAuthorship W4311658429A5067433800 @default.
• W4311658429 hasAuthorship W4311658429A5072459089 @default.
• W4311658429 hasAuthorship W4311658429A5084421656 @default.
• W4311658429 hasAuthorship W4311658429A5085802645 @default.
• W4311658429 hasBestOaLocation W43116584291 @default.
• W4311658429 hasConcept C121608353 @default.
• W4311658429 hasConcept C126322002 @default.
• W4311658429 hasConcept C143998085 @default.
• W4311658429 hasConcept C207103383 @default.
• W4311658429 hasConcept C2776694085 @default.
• W4311658429 hasConcept C2777701055 @default.
• W4311658429 hasConcept C2780030458 @default.
• W4311658429 hasConcept C2780057760 @default.
• W4311658429 hasConcept C2781413609 @default.
• W4311658429 hasConcept C44249647 @default.
• W4311658429 hasConcept C71924100 @default.
• W4311658429 hasConcept C90924648 @default.
• W4311658429 hasConceptScore W4311658429C121608353 @default.
• W4311658429 hasConceptScore W4311658429C126322002 @default.
• W4311658429 hasConceptScore W4311658429C143998085 @default.
• W4311658429 hasConceptScore W4311658429C207103383 @default.
• W4311658429 hasConceptScore W4311658429C2776694085 @default.
• W4311658429 hasConceptScore W4311658429C2777701055 @default.
• W4311658429 hasConceptScore W4311658429C2780030458 @default.
• W4311658429 hasConceptScore W4311658429C2780057760 @default.
• W4311658429 hasConceptScore W4311658429C2781413609 @default.
• W4311658429 hasConceptScore W4311658429C44249647 @default.
• W4311658429 hasConceptScore W4311658429C71924100 @default.
• W4311658429 hasConceptScore W4311658429C90924648 @default.
• W4311658429 hasIssue "9" @default.
• W4311658429 hasLocation W43116584291 @default.
• W4311658429 hasLocation W43116584292 @default.
• W4311658429 hasLocation W43116584293 @default.
• W4311658429 hasOpenAccess W4311658429 @default.
• W4311658429 hasPrimaryLocation W43116584291 @default.
• W4311658429 hasRelatedWork W2155654588 @default.
• W4311658429 hasRelatedWork W2296139876 @default.

• next